Testosterone Enanthate

Nandrolone potentiates erythropoiesis beyond an additive effect, so haematocrit on the combination exceeds what either dose predicts on its own.

Both raise haemoglobin and haematocrit and both suppress FSH, so the combination pushes two markers in the same direction at once.

Boldenone is the strongest erythropoietic compound in common use and its 14 day ester keeps compounding, so haematocrit climbs late in a cycle that looked controlled at week 8.

Clenbuterol adds sustained sympathetic drive and cardiac stress to a testosterone protocol that is already raising haematocrit, viscosity and blood pressure.

Adding myostatin blockade to an androgen stacks the blood pressure and lipid cost of rapid lean mass gain without adding a new mechanism to manage it.

Two aromatising compounds together produce an estradiol rise, water retention and blood pressure climb that neither dose predicts alone.

Adding a SARM to a testosterone base adds hepatic risk and HDL suppression without adding anything the androgen receptor was not already saturated with.

Oxymetholone adds the most severe hepatotoxicity of the common orals plus a strong erythropoietic drive to a testosterone base that is already raising haematocrit.

Stanozolol drops HDL by more than half on top of a testosterone base that is already suppressing it, producing one of the worst lipid profiles in common use.

Methasterone can produce cholestatic liver injury within two to three weeks, and the testosterone base does nothing to offset it while adding its own lipid and blood pressure load.

Trenbolone's mineralocorticoid and sympathetic drive lands on top of testosterone's haematocrit and lipid effects, and blood pressure is where the combination shows first.

Running MENT on a testosterone base doubles the aromatising substrate, but only one of the two estrogens produced is visible on a standard assay.

Turinabol adds no estradiol but still adds hepatic load, SHBG suppression and a substantial HDL hit to the testosterone base.